Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
Business Wire•02/11/2026•16:05 ET
0
Key Highlights
- ➤Alpha Cognition will report Q3 2026 results November 11 after market close
- ➤Management will provide a business update during the November 11 conference call
- ➤ZUNVEYL is approved for Alzheimer’s disease treatment
- ➤ALPHA-1062 is being developed with memantine and as an intranasal mTBI formulation
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2026 financial results and provide a business update on Wednesday, November 11, 2026, at 4:30 p.m. ET, after market close.
Get started
Create a free account to read the full story.